U.S. Markets closed

Emergent BioSolutions Inc. (EBS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
53.85-0.54 (-0.99%)
At close: 4:00PM EDT

Emergent BioSolutions Inc.

400 Professional Drive
Suite 400
Gaithersburg, MD 20879
United States
240 631 3200
http://www.emergentbiosolutions.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees2,200

Key Executives

NameTitlePayExercisedYear Born
Mr. Fuad El-HibriFounder & Exec. Chairman1.2M9.68M1958
Mr. Robert G. KramerCEO, Pres & Exec. Director2.13MN/A1957
Mr. Richard S. LindahlExec. VP, CFO & Treasurer1.02MN/A1964
Mr. Atul SaranExec. VP of Corp. Devel., Gen. Counsel & Corp. Sec.983.57kN/A1973
Mr. Adam R. HaveyExec. VP of Bus. Operations1M1.44M1971
Mr. Sean M. KirkExec. VP of Manufacturing & Technical OperationsN/AN/A1975
Mr. Howard AndersonSr. VP & Chief Information OfficerN/AN/AN/A
Mr. Robert G. BurrowsVP of Investor RelationsN/AN/AN/A
Ms. Lynn KiefferVP of Corp. CommunicationsN/AN/AN/A
Ms. Nina DeLorenzoSr. VP of Global Communications & Public AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Emergent BioSolutions Inc.’s ISS Governance QualityScore as of July 1, 2021 is 6. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 7; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.